-
2023-504655-27-00
5
2024-12-23
Primary Indeterminate Lesions or Small Choroidal Melanoma
-
2024-513077-48-00
5
2024-12-19
O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
-
2024-511879-16-00
5
2024-12-12
Prurigo Nodularis
-
2023-505283-11-00
6
2024-12-10
Relapsing forms of Multiple Sclerosis (RMS)
-
2023-503630-44-00
10
2024-11-20
Treatment of moderate-to-severe Atopic dermatitis
-
2024-511404-17-00
5
2024-10-07
Unresectable or metastatic NRAS mutant cutaneous melanoma
-
2023-504231-41-01
10
2024-10-02
Locally advanced or metastatic urothelial cancer
-
2023-508693-29-00
3
2024-09-19
Active, moderate-to-severe TED
-
2023-504214-30-00
5
2024-06-27
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
-
2023-504308-27-00
5
2024-06-06
non-squamous non-small cell lung cancer
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2023-505945-19-00
4
2024-03-08
stage II melanoma
-
2022-501980-42-00
5
2023-12-21
Anemia associated with Chronic Kidney Disease
-
2024-511337-35-00
4
2023-11-16
The trial will include patients with so called "fusion-driven", metast
-
2022-502286-16-00
5
2023-10-27
Primary Generalized Tonic-Clonic Seizures
-
2023-504265-23-00
4
2023-10-23
Crohn's disease
-
2023-509810-13-00
4
2023-05-13
Acute Lymphoblastic Leukemia (ALL)
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2023-507518-28-00
5
2022-09-13
Acute myeloid leukemia
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2024-512657-24-00
10
2014-03-27
Acute Lymphoblastic Leukaemia